Highlights the importance of recognizing and treating depression as a significant comorbidity affecting quality of life in patients with pulmonary arterial hypertension.
May support depression screening in PAH care; leaves open whether treatment improves outcomes in prospective trials.
The recent identification of depression as an important comorbidity in pulmonary arterial hypertension (PAH)12 is leading to a broad array of efforts to further refine our understanding of this disorder, enhance patient and provider education about it, and encourage prompt recognition, appropriate diagnosis, and treatment of affected individuals. We will provide an update on the nature and extent of the problem, and describe ongoing and future efforts to address this very important determinant of quality of life and possible long-term outcome in patients with PAH.
No takes yet. Share an insight, caveat, or question.
McCollister et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: